Literature DB >> 19715872

Use of small donors (<28 kg) for pancreas transplantation.

H G Illanes1, C M Quarin, R Maurette, N G Sánchez, L Reniero, D H Casadei.   

Abstract

OBJECTIVE: Small donors have long been considered a potential source of organs for simultaneous pancreas-kidney transplantation (SPK) and pancreas transplantation alone (PTA). Our aim was to analyze our experience with SPK and PTA using small donors weighing <28 kg. PATIENTS AND METHODS: Between September 2006 and October 2008, we performed 68 SPK, 3 PTA, and 3 pancreas after kidney transplantations (PAK). All recipients were adults with type 1 diabetes mellitus, including 8 who received small donor organs (<28 kg): 6 SPK and 2 PTA. We used 3 graft combinations for SPK: pancreas and single kidney; pancreas and en bloc kidneys; and en bloc dual kidney-pancreas. In contrast, we used conventional grafts for PTA. Mean weight among donors was 20.82 kg (range, 9.6-27 kg).
RESULTS: We observed neither delayed graft function nor mortality. At a follow-up of approximately 281 days, all patients were free of insulin and dialysis treatments.
CONCLUSIONS: Kidneys and pancreas from donors weighing <28 kg can be used in adult type 1 diabetic patients with excellent results. These small pediatric donors enabled us to enlarge the number of transplantations by 10.81%.

Entities:  

Mesh:

Year:  2009        PMID: 19715872     DOI: 10.1016/j.transproceed.2009.05.025

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Pancreatic Grafts from Pediatric Donors Do Not Appear to Grow After Transplantation into Adults.

Authors:  Kaerli Christensen; Anne Kennedy; Robin Kim; Eryberto Martinez; Jeffrey Campsen
Journal:  Cureus       Date:  2018-09-26

2.  The Outcomes of Pancreatic Transplantation from Pediatric Donors-A Single Institution Experience.

Authors:  Taihei Ito; Takashi Kenmochi; Naohiro Aida; Kei Kurihara; Akihiro Kawai; Atsushi Suzuki; Megumi Shibata; Izumi Hiratsuka; Midori Hasegawa
Journal:  J Clin Med       Date:  2019-09-04       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.